Abstract | PURPOSE: We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODS: A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTS: One patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. CONCLUSIONS: The histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations.
|
Authors | Antoine G van der Heijden, Paula M J Moonen, Erik B Cornel, Henk Vergunst, Theo M de Reijke, Erika van Boven, Evert J Barten, Rajiv Puri, Coenraad K van Kalken, J Alfred Witjes |
Journal | The Journal of urology
(J Urol)
Vol. 176
Issue 4 Pt 1
Pg. 1349-53; discussion 1353
(Oct 2006)
ISSN: 0022-5347 [Print] United States |
PMID | 16952629
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Aziridines
- Indolequinones
- apaziquone
|
Topics |
- Administration, Intravesical
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Aziridines
(administration & dosage, adverse effects)
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Cohort Studies
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Indolequinones
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Treatment Outcome
- Urinary Bladder Neoplasms
(drug therapy, pathology)
|